On the afternoon of April 9th, local time, the European Drug Administration issued an announcement that its drug alert risk assessment committee had launched an evaluation investigation into the occurrence of capillary leakage syndrome after being vaccinated against AstraZeneca.
The European Drug Administration said that it has found five such diseases in its database that reported suspected side effects of drugs. Patients have plasma infiltration from blood vessels to tissue gaps, which causes edema and blood pressure to drop. In response, the European Drug Administration will evaluate it through all the data currently available, so as to determine whether the disease is related to AstraZeneca vaccine.
On April 7th local time, the European Drug Administration has further determined that AstraZeneca vaccine may cause abnormal thrombosis symptoms accompanied by thrombocytopenia. But the agency also said that this is a very rare side effect.
However, when the relevant conclusions were confirmed, EU countries such as Belgium, Italy and Spain decided to limit the number of people vaccinated against AstraZeneca to 55 years old or over.